Find Droxidopa manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

81 RELATED EXCIPIENT COMPANIES

148EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 23651-95-8, L-dops, Dops, Northera, 3916-18-5, (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
Molecular Formula
C9H11NO5
Molecular Weight
213.19  g/mol
InChI Key
QXWYKJLNLSIPIN-JGVFFNPUSA-N
FDA UNII
24A0V01WKS

Droxidopa
A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.
The physiologic effect of droxidopa is by means of Increased Blood Pressure.
1 2D Structure

Droxidopa

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
2.1.2 InChI
InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
2.1.3 InChI Key
QXWYKJLNLSIPIN-JGVFFNPUSA-N
2.1.4 Canonical SMILES
C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O
2.1.5 Isomeric SMILES
C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
2.2 Other Identifiers
2.2.1 UNII
24A0V01WKS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3,4 Dihydroxyphenylserine

2. 3,4 Threo Dops

3. 3,4-dihydroxyphenylserine

4. 3,4-threo-dops

5. Dl Threo 3,4 Dihydroxyphenylserine

6. Dl-threo-3,4-dihydroxyphenylserine

7. Droxidopa, (dl-tyr)-isomer

8. Erythro 3,4 Dihydroxyphenylserine

9. Erythro-3,4-dihydroxyphenylserine

10. Threo Dops

11. Threo-dops

2.3.2 Depositor-Supplied Synonyms

1. 23651-95-8

2. L-dops

3. Dops

4. Northera

5. 3916-18-5

6. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid

7. Dl-threo-droxidopa

8. Dl-threo-3,4-dihydroxyphenylserine

9. Dl-threo-dops

10. Threo-dopaserine

11. L-threodops

12. L-threo-dops

13. Dl-threo-dihydroxyphenylserine

14. Threo-dihydroxyphenylserine

15. Sm 5688

16. Chebi:31524

17. L-dihydroxyphenylserine

18. Droxidopa (l-dops)

19. Serine, 3-(3,4-dihydroxyphenyl)-, Dl-threo-

20. L-threo-dihydroxyphenylserine

21. 24a0v01wks

22. J7a92w69l7

23. Dl-threo-beta-(3,4-dihydroxyphenyl)serine

24. Droxydopa

25. L-threo-3,4-dihydroxyphenylserine

26. Norethra

27. Droxidopa [latin]

28. Threo-beta,3-dihydroxy-dl-tyrosine

29. Einecs 223-480-5

30. Beta,3-dihydroxy-dl-tyrosine Threo-

31. 3,4-dihydroxyphenylserine

32. Brn 2852792

33. Droxidopum

34. L-tyrosine, Beta,3-dihydroxy-, Threo-

35. Unii-24a0v01wks

36. Dl-threo-3-(3,4-dihydroxyphenyl)serine

37. Droxidopa [usan:inn:jan]

38. Unii-j7a92w69l7

39. (2rs,3rs)-2-amino-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic Acid

40. L-threo 3,4-dihydroxyphenylserine

41. Northera (tn)

42. L-threo Dops

43. Dops (tn)

44. L-threo-3-(3,4-dihydroxyphenyl)serine

45. Dl-tyrosine, Beta,3-dihydroxy-, Threo-

46. Droxidopa [inn]

47. Droxidopa [jan]

48. Droxidopa [mi]

49. Threo-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid

50. Droxidopa [usan]

51. Dl-tyrosine, .beta.,3-dihydroxy-, Threo-

52. Droxidopa [vandf]

53. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic Acid

54. Droxidopa [mart.]

55. Droxidopa [who-dd]

56. 1-14-00-00685 (beilstein Handbook Reference)

57. 1260173-94-1

58. Schembl134299

59. Gtpl7391

60. Droxidopa (jp17/usan/inn)

61. Droxidopa [orange Book]

62. Chembl2103827

63. Dtxsid6046422

64. Droxidopa (l-dops,sm-5688)

65. Dtxsid201017236

66. Bcp06516

67. Zinc1482049

68. Bdbm50103611

69. Mfcd00799030

70. S3041

71. Sm5688

72. (betar)-beta,3-dihydroxy-l-tyrosine

73. L-dops, >=98% (hplc)

74. (2s,3r)-3,4-dihydroxy-phenylserine

75. Akos015889899

76. Ccg-222060

77. Db06262

78. Sm-5688

79. Ncgc00344531-04

80. As-61328

81. Hy-13458

82. L-tyrosine, Beta,3-dihydroxy-, (betar)-

83. D4235

84. L-tyrosine, Beta,3-dihydroxy-, (beta-r)-

85. Threo-3,4-dihydroxyphenylserine, L-

86. 3,4-dihydroxyphenylserine-threo, Dl-

87. Dl-threo- Beta -(3,4-dihydroxyphenyl)serine

88. (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine

89. D01277

90. D90266

91. Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-

92. Ab01566868_01

93. 916a185

94. A816824

95. Q907853

96. Sr-01000883755

97. Q-201050

98. Sr-01000883755-1

99. L-tyrosine, .beta.,3-dihydroxy-, (.beta.r)-

100. D-tyrosine, .beta.,3-dihydroxy-, (.beta.s)-rel-

101. 23651-95-8,1260173-94-1(hcl)

102. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid

103. (2s,3r)-3-(3,4-dihydroxyphenyl)-2-amino-3-hydroxypropanoic Acid

104. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic Acid

105. (2rs,3rs)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic Acid

106. (-)-(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 213.19 g/mol
Molecular Formula C9H11NO5
XLogP3-3.2
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass213.06372245 g/mol
Monoisotopic Mass213.06372245 g/mol
Topological Polar Surface Area124 Ų
Heavy Atom Count15
Formal Charge0
Complexity235
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameNorthera
PubMed HealthDroxidopa (Oral route)
Drug ClassesAdrenergic, Vasopressor
Drug LabelNORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is...
Active IngredientDroxidopa
Dosage FormCapsule
RouteOral
Strength200mg; 300mg; 100mg
Market StatusPrescription
CompanyLundbeck Na

2 of 2  
Drug NameNorthera
PubMed HealthDroxidopa (Oral route)
Drug ClassesAdrenergic, Vasopressor
Drug LabelNORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is...
Active IngredientDroxidopa
Dosage FormCapsule
RouteOral
Strength200mg; 300mg; 100mg
Market StatusPrescription
CompanyLundbeck Na

4.2 Drug Indication

For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.


5.2 MeSH Pharmacological Classification

Antiparkinson Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
DROXIDOPA
5.3.2 FDA UNII
J7A92W69L7
5.3.3 Pharmacological Classes
Increased Blood Pressure [PE]; Catecholamines [CS]
5.4 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01C - Cardiac stimulants excl. cardiac glycosides

C01CA - Adrenergic and dopaminergic agents

C01CA27 - Droxidopa


5.5 Absorption, Distribution and Excretion

Absorption

Oral bioavailability is 90%.


Route of Elimination

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.


5.6 Metabolism/Metabolites

Droxidopa is metabolized by aromatic L-amino acid decarboxylase.


5.7 Biological Half-Life

2-3 hours.


5.8 Mechanism of Action

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.


API SUPPLIERS

read-more
read-more

01

Lifecare Laboratories Pvt Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLifecare Labs has been developing innovative products in specialist areas of medicine.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LifeCare Laboratories

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

03

Clarochem Ireland

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Clarochem Ireland

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

04

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Quimica Sintetica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Quimica Sintetica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF VMF Others AUDIT
blank

07

Viatris

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Viatris

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Piramal Pharma Solutions

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Piramal Pharma Solutions

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

09

Lupin Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Lupin Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT
blank

10

Sumitomo Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Sumitomo Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Clarochem Ireland Ltd

Ireland

USDMF

arrow
DDL Conference
Not Confirmed

01

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-03-20

Pay. Date : 2019-01-31

DMF Number : 33459

Submission : 2019-01-04

Status : Active

Type : II

blank

02

DDL Conference
Not Confirmed

02

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-01-10

Pay. Date : 2020-11-25

DMF Number : 35368

Submission : 2020-11-27

Status : Active

Type : II

blank

03

DDL Conference
Not Confirmed

03

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-02-02

Pay. Date : 2017-11-08

DMF Number : 32184

Submission : 2017-12-08

Status : Active

Type : II

blank

04

DDL Conference
Not Confirmed

04

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2017-11-16

Pay. Date : 2017-10-17

DMF Number : 32032

Submission : 2017-10-06

Status : Active

Type : II

blank

05

DDL Conference
Not Confirmed

05

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-01-12

Pay. Date : 2017-10-10

DMF Number : 31514

Submission : 2017-03-28

Status : Active

Type : II

blank

06

Piramal Pharma Ltd

U.S.A

USDMF

arrow
DDL Conference
Not Confirmed

06

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-02-25

Pay. Date : 2019-12-31

DMF Number : 34258

Submission : 2019-12-20

Status : Active

Type : II

blank

07

Quimica Sintetica Sa

Spain

USDMF

arrow
DDL Conference
Not Confirmed

07

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-02-08

Pay. Date : 2017-12-06

DMF Number : 32264

Submission : 2017-11-24

Status : Active

Type : II

blank

08

DDL Conference
Not Confirmed

08

DDL Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20556

Submission : 2007-05-23

Status : Inactive

Type : II

blank

09

DDL Conference
Not Confirmed

09

DDL Conference
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 34389

Submission : 2019-12-31

Status : Active

Type : II

blank

10

DDL Conference
Not Confirmed

10

DDL Conference
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-11-15

Pay. Date : 2018-08-22

DMF Number : 33089

Submission : 2018-09-18

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Droxidopa

Registration Number : 218MF10452

Registrant's Address : Rejiawan, Dashiba, Nan an, Chongqing China

Initial Date of Registration : 2006-04-27

Latest Date of Registration : 2007-02-13

blank

02

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Droxidopa

Registration Number : 222MF10282

Registrant's Address : No. 8 Jiangqiao Road, Nan an District Chongqing China

Initial Date of Registration : 2010-12-24

Latest Date of Registration : 2010-12-24

blank

03

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Droxidopa

Registration Number : 218MF10680

Registrant's Address : Renjiawan, Dashiba, Nan an Chongqing 40006, China

Initial Date of Registration : 2006-08-11

Latest Date of Registration : 2006-08-11

blank

04

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Drooxidopa

Registration Number : 221MF10115

Registrant's Address : 25, Barangongdan-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

Initial Date of Registration : 2009-06-16

Latest Date of Registration : 2009-06-16

blank

05

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Drooxidopa

Registration Number : 228MF10144

Registrant's Address : 25, Barangongdan-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

Initial Date of Registration : 2016-08-03

Latest Date of Registration : 2016-08-03

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

Lupin Ltd

India
DDL Conference
Not Confirmed
arrow

Lupin Ltd

India
arrow
DDL Conference
Not Confirmed

Droxidopa IH

Date of Issue : 2022-06-07

Valid Till : 2025-06-16

Written Confirmation Number : WC-0049

Address of the Firm : Block 21, Dabhasa, Padra Taluka, Vadodara-391 440

blank

02

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Droxidopa IH

Date of Issue : 2019-07-26

Valid Till : 2022-08-08

Written Confirmation Number : WC-0383

Address of the Firm : Sy. No.455/A, 455/AA, 455/E & 455/EE Chandampet Village Shankarampet Mandal Meda...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

Droxidopa

Registrant Name : Polaris AI Pharma Co., Ltd.

Registration Date : 2018-08-14

Registration Number : 20180814-211-J-252

Manufacturer Name : Estec Pharma Co., Ltd. @ [Pr...

Manufacturer Address : 25 Balan Industrial Complex Road, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, 34 Block 10...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

arrow
DDL Conference
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Flag India
Digital Content Digital Content

DROXIDOPA

NDC Package Code : 58159-049

Start Marketing Date : 2016-07-20

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (35kg/35kg)

Marketing Category : BULK INGREDIENT

Nuray Chemicals

02

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 42973-237

Start Marketing Date : 2017-12-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 76278-1120

Start Marketing Date : 2016-11-25

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

04

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 70966-0006

Start Marketing Date : 2018-01-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 69766-032

Start Marketing Date : 2017-03-28

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 65085-0071

Start Marketing Date : 2023-01-02

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

07

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 53069-1060

Start Marketing Date : 2014-02-18

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

DDL Conference
Not Confirmed
arrow
arrow
DDL Conference
Not Confirmed

DROXIDOPA

NDC Package Code : 38217-0030

Start Marketing Date : 2014-02-18

End Marketing Date : 2030-12-31

Dosage Form (Strength) : POWDER (40kg/1)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Co-Processed Excipients

read-more
read-more

Empty Capsules

read-more
read-more

Lubricants & Glidants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Granulation

read-more
read-more

Parenteral

read-more
read-more

Coloring Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty